Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 5/2021

01-05-2021 | Glioma | Retraction Note

Retraction Note to: Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR‑181 level

Authors: Anjing Gong, Na Ge, Weicheng Yao, Luxiang Lu, Hui Liang

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2021

Login to get access

Excerpt

The authors have retracted this article [1]. After recent further analysis of the data presented in Figures 4 and 6, it was determined that these data do not support the study conclusion that aplysin enhances glioma cell sensitivity to temozolomide. …
Literature
1.
Gong A, Ge N, Yao W et al (2014) Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level. Cancer Chemother Pharmacol 74:531–538CrossRef
Metadata
Title
Retraction Note to: Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR‑181 level
Authors
Anjing Gong
Na Ge
Weicheng Yao
Luxiang Lu
Hui Liang
Publication date
01-05-2021
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2021
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-020-04166-1

Other articles of this Issue 5/2021

Cancer Chemotherapy and Pharmacology 5/2021 Go to the issue

Original Article

A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours

Original Article

Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer

Original Article

Carboxylesterase 1 polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine

Original Article

A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies

Original Article

Early myelostimulation in patients with locally advanced gastric cancer after fluorouracil plus platinum-based neoadjuvant chemotherapy is related to poor prognosis

Original Article

Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits